Hopp til innhold
NHI.no
Annonse

HPV-infeksjon: Kan HPV forebygges?

Innhold i artikkelen

Det er vist at HPV-infeksjon på livmorhalsen forekommer hyppigere hos kvinner som har hatt mange seksualpartnere og som ikke har brukt kondom. Infeksjonen varer også lenger, med større risiko for celleforandringer, hos dem som røyker. Her ligger det altså en mulighet for forebygging.

Annonse

Alle jenter og gutter i 7. klasse tilbys vaksine mot HPV infeksjon gjennom Barnevaksinasjonsprogrammet. Vaksinen beskytter mot HPV-typene 16 og 18, som forårsaker de fleste (over 70 prosent) av tilfellene av livmorhalskreft. Vaksinen som benyttes i programmet, beskytter ikke mot kjønnsvorter (HPV type 6 og 11). Forskning har imidlertid vist at de vaksinerte kan utvikle en beskyttelse også mot andre HPV-typer enn det vaksinen har inneholdt, det kalles kryssbeskyttelse. Les mer her: HPV-vaksine

Dette dokumentet er basert på det profesjonelle dokumentet Humant papillomavirus (HPV) . Referanselisten for dette dokumentet vises nedenfor

  1. Kombe AJ, Li B, Zahid A, et al. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2021 Jan 20;8:552028. PMID: 33553082 PubMed
  2. Folkehelseinstituttet. Humant papillomavirus (HPV), genitale infeksjoner – håndbok for helsepersonell. Smittevernhåndboka. Oslo: Folkehelseinstituttet; sist oppdatert 09.07.2024. Siden besøkt 23.10.2024 www.fhi.no
  3. Quinlan JD. Human Papillomavirus: Screening, Testing, and Prevention. Am Fam Physician. 2021 Aug 1;104(2):152-159. PMID: 34383440 PubMed
  4. Molden T, Feiring B, Ambur OH, et al. Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated birth cohorts. Papillomavirus Res. 2016 Dec;2:153-158. PMID: 29074174 PubMed
  5. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007; 196 (10): 1447. pmid:18008222 PubMed
  6. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2024. Siden besøkt 28.10.2024 gco.iarc.who.int
  7. Kreftregisteret. Livmorhalskreft. Oslo: Kreftregisteret. Sist oppdatert 14.06.2024. Siden besøkt 23.10.2024 www.kreftregisteret.no
  8. Kreftregisteret. Årsrapport 2023. Screeningaktivitet og resultater fra Livmorhalsprogrammet. Oslo: Kreftregisteret; 01.07.2024. Siden besøkt 23.10.2024 www.kreftregisteret.no
  9. Kreftregisteret. Kvalitetsmanualen. Oslo: Kreftregisteret. Sist oppdatert 09.04.204, siden besøkt 23.10.2024 www.kreftregisteret.no
  10. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. The Lancet Infectious Diseases 2009; 9 (6): 347-56. PMID: 19467474 PubMed
  11. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191: 731-8. PubMed
  12. Burchell AN, Winer RL, de Sanjos S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24(suppl 3): S3/52-S3/61.
  13. Kreimer AR, Campbell CM, Lin HY, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013. PMID: 23827089 PubMed
  14. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. pmid: 34292926 PubMed
  15. Hernandez BY, McDuffie K, Zhu X, et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev 2005; 14: 2550-6. PubMed
  16. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354: 2645-54. PMID: 16790697 PubMed
  17. Wen LM, Estcourt CS, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect 1999; 75: 312-6. PubMed
  18. Jensen KE, Thomsen LT, Schmiedel S, et al. Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: a cohort study. Sex Transm Infect 2014 Nov;90(7):550-5. PMID: 24728044 PubMed
  19. Kaderli R, Schnüriger B, Brügger LE. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis 2014. pmid:24935346 PubMed
  20. Oh HY, Kim MK, Seo S, et al. Alcohol consumption and persistent infection of high-risk human papillomavirus. Epidemiol Infect. 2015 May;143(7):1442-50. PMID: 25185457 PubMed
  21. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-80. PubMed
  22. Bruggink SC, Eekhof JA, Egberts PF, et al. Natural course of cutaneous warts among primary schoolchildren: a prospective cohort study. Ann Fam Med. 2013 Sep-Oct;11(5):437-41. PMID: 24019275 PubMed
  23. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005; 32(suppl 1): S82-S90. PMID: 15753016 PubMed
  24. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006; 208: 152-64. PubMed
  25. Naucler P, Ryd W, Tärnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97. PMID: 17942872 PubMed
  26. Tainio K, Athanasiou A, Tikkinen KAO et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018; 360 :k499. PMID: 29487049 PubMed
  27. Koeneman MM, van Lint FHM, van Kuijk SMJ et al. A prediction model for spontaneous regression of cervical intraepithelial neoplasia grade 2, based on simple clinical parameters. Hum Pathol 2017; 59: 62-9. pmid:27697590 PubMed
  28. Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020 Nov 15;17(4):864-878. PMID: 33299640 PubMed
  29. Faber MT, Sand FL, Albieri V, et al. Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva. Int J Cancer. 2017 Sep 15;141(6):1161-1169. PMID: 28577297 PubMed
  30. Sinno AK, Saraiya M, Thompson TD, et al. Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. Obstet Gynecol. 2014 Apr;123(4):817-21. PMID: 24785610 PubMed
  31. Olesen TB, Sand FL, Rasmussen CL, et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2019 Jan;20(1):145-158. PMID: 30573285 PubMed
  32. Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022 May;19(5):306-327. PMID: 35105976 PubMed
  33. Nygård M, Andreassen T, Berland J, et al. 2013. HPV-test i primærscreening mot livmorhalskreft. Kontrollert implementering og evaluering av forbedret helsetjeneste. Oslo, Helsedirektoratet. www.kreftregisteret.no
  34. Pathak N, Dodds J, Zamora J, et al. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ. 2014 Sep 16;349:g5264. PMID: 25232064 PubMed
  35. Leinonen MK, Schee K, Jonassen CM et al. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. J Clin Virol 2018; 99: 22-30. pmid:29289814 PubMed
  36. Arbyn M, Smith SB, Temin S et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 2018. PMID: 30518635 PubMed
  37. Polman NJ, Ebisch RMF, Heideman DAM et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol 2019; 20: 229-38. pmid:30658933 PubMed
  38. Kreftregisteret. HPV hjemmetest via fastleger. HPV hjemmetest (for helsepersonell). Oslo: Kreftregisteret. Sist oppdatert 21.10.2024. Siden besøkt 27.10.2024 www.kreftregisteret.no
  39. Giuliano AR, Lee J-H, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011 Mar 12;377(9769):932-40. PMID: 2136744 PubMed
  40. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35: 1127-34. PubMed
  41. Cranston RD, Hart SD, Gornbein JA, Hirschowitz SL, Cortina G, Moe AA. The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men. Int J STD AIDS 2007; 18: 77-80. PubMed
  42. Folkehelseinstituttet. HPV-vaksine (Humant papillomavirus) - håndbok for helsepersonell. Vaksinasjonshåndboka. Oslo: Folkhelseinstituttet, sist oppdatert 28.06.2024. Siden besøkt 28.10.2024 www.fhi.no
  43. Kavanagh K, Pollock KG, Cuschieri K et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017; 17: 1293-302. pmid:28965955 PubMed
  44. Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: epub301. pmid:19586656 PubMed
  45. WHO position paper: Human papillomavirus vaccines - May 2017. Wkly Epidemiol Rec 2017;92(19):241 PubMed
  46. Gilca V, Sauvageau C, Panicker G,et al. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Vaccine. 2018 Nov 12;36(46):7017-7024. PMID: 30314913 PubMed
  47. Fairley CK, Hockin JS, Gurrin LC, et al. Rapid decline in presentations for genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women. Sex Transm Infect 2009; : PMID: 19837728 PubMed
  48. Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016 Mar;137(3):e20151968. PMID: 26908697 PubMed
Annonse
Annonse